Profile data is unavailable for this security.
About the company
Probi AB is a Sweden-based company engaged in the probiotics research and development. The Company’s activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies and firms related to the production of probiotics and self-care goods. Its brands portfolio comprises two trademarks: Probi Digestis and Probi Defendum. The Company's partners include Danone, Skanemejerier, NextFoods, Sanum Polska, Heinz, Kraft Foods, and Institut Rosell, among others. The Company is a parent of Probi Food AB and Probi Feed AB.
- Revenue in SEK (TTM)607.54m
- Net income in SEK-602.00k
- Incorporated1991
- Employees167.00
- LocationProbi ABIdeongatan 1ALUND 223 70SwedenSWE
- Phone+46 462868920
- Fax+46 462868928
- Websitehttps://probi.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IRLAB Therapeutics AB | 5.68m | -157.30m | 693.97m | 28.00 | -- | 9.06 | -- | 122.22 | -3.03 | -3.03 | 0.1095 | 1.48 | 0.0274 | -- | 0.4652 | 218,384.60 | -75.97 | -27.12 | -94.23 | -30.42 | -1,952.47 | -72.18 | -2,770.38 | -155.57 | -- | -- | 0.2646 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
Moberg Pharma AB (publ) | 820.00k | -22.56m | 842.10m | 9.00 | -- | 1.33 | -- | 1,026.95 | -1.09 | -1.09 | 0.0379 | 21.63 | 0.0014 | -- | 0.2841 | -- | -3.81 | -- | -3.96 | -- | 60.00 | -- | -2,751.22 | -- | 1.73 | -- | 0.0073 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
Vistin Pharma ASA | 435.59m | 55.88m | 960.66m | 77.00 | 17.19 | 3.25 | 13.05 | 2.21 | 1.27 | 1.27 | 9.88 | 6.70 | 1.11 | 2.31 | 7.44 | 5,692,663.00 | 14.28 | 1.73 | 18.93 | 2.11 | 59.93 | 58.92 | 12.83 | 2.36 | 0.8536 | 32.96 | 0.0934 | -- | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
Infant Bacterial Therapeutics AB | 0.00 | -128.42m | 1.28bn | 9.00 | -- | 4.79 | -- | -- | -9.96 | -9.96 | 0.00 | 20.59 | 0.00 | -- | -- | 0.00 | -37.63 | -16.11 | -43.78 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
Photocure ASA | 509.24m | 4.79m | 1.57bn | 102.00 | 332.86 | 3.28 | 47.82 | 3.09 | 0.1755 | 0.1755 | 19.02 | 17.82 | 0.7215 | 0.9144 | 7.93 | 5,024,010.00 | 0.6789 | -3.06 | 0.7682 | -3.54 | 94.65 | 93.64 | 0.941 | -5.15 | 4.33 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
Probi AB | 607.54m | -602.00k | 3.42bn | 167.00 | -- | 2.40 | 35.62 | 5.63 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
Flerie AB | 108.34m | -56.48m | 3.66bn | 7.00 | -- | 1.06 | -- | 33.79 | -0.1037 | -0.1037 | 0.2028 | 0.443 | 0.3559 | -- | -- | 15,477,000.00 | -18.55 | -37.64 | -21.24 | -41.14 | -46.98 | -450.51 | -52.13 | -454.62 | -- | -- | 0.0086 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
Swedencare AB (publ) | 2.41bn | 71.50m | 9.04bn | 552.00 | 126.43 | 1.17 | 23.58 | 3.75 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
BioGaia AB | 1.30bn | 371.25m | 11.98bn | 211.00 | 33.51 | 5.74 | 30.28 | 9.22 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
Calliditas Therapeutics AB | 1.31bn | -524.82m | 12.29bn | 219.00 | -- | 92.11 | -- | 9.37 | -9.78 | -9.78 | 24.43 | 2.24 | 0.7541 | 3.16 | 8.97 | 6,723,169.00 | -30.19 | -26.46 | -38.05 | -30.27 | 95.01 | -- | -40.03 | -76.59 | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 31 Dec 2023 | 1.06m | 9.28% |
Handelsbanken Fonder ABas of 31 May 2024 | 70.00k | 0.61% |
Nordea Investment Management AB (Finland)as of 31 Aug 2023 | 67.24k | 0.59% |
Deka Investment GmbHas of 31 Mar 2024 | 60.98k | 0.54% |
SEB Investment Management ABas of 31 May 2024 | 59.10k | 0.52% |
FCG Fonder ABas of 31 Dec 2023 | 28.54k | 0.25% |
Skandia Investment Management ABas of 30 Apr 2024 | 18.29k | 0.16% |
MFS International (UK) Ltd.as of 31 May 2024 | 16.25k | 0.14% |
Storebrand Asset Management ASas of 31 Jan 2024 | 4.20k | 0.04% |
Dimensional Fund Advisors LPas of 31 May 2024 | 2.79k | 0.03% |